Jason P Lott1, Denise M Boudreau2,3, Ray L Barnhill4, Martin A Weinstock5,6,7, Eleanor Knopp8,9, Michael W Piepkorn8,10, David E Elder11, Steven R Knezevich12, Andrew Baer2, Anna N A Tosteson13,14,15, Joann G Elmore16. 1. Cornell Scott-Hill Health Center, New Haven, Connecticut. 2. Kaiser Permanente Washington Health Research Institute, Seattle. 3. Departments of Pharmacy and Epidemiology, University of Washington, Seattle. 4. Department of Pathology, Institut Curie, and Faculty of Medicine, University of Paris Descartes, Paris, France. 5. Departments of Dermatology and Epidemiology, Brown University, Providence, Rhode Island. 6. Center for Dermatoepidemiology, Department of Veterans Affairs Medical Center, Providence, Rhode Island. 7. Department of Dermatology, Rhode Island Hospital, Providence, Rhode Island. 8. Division of Dermatology, Department of Medicine, University of Washington, Seattle. 9. Group Health Capitol Hill Campus, Seattle, Washington. 10. Dermatopathology Northwest, Bellevue, Washington. 11. Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia. 12. Pathology Associates, Clovis, California. 13. The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire. 14. Department of Medicine Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire. 15. Norris Cotton Cancer Center, Lebanon, New Hampshire. 16. Department of Medicine, University of Washington School of Medicine, Seattle.
Abstract
Importance: Population-based information on the distribution of histologic diagnoses associated with skin biopsies is unknown. Electronic medical records (EMRs) enable automated extraction of pathology report data to improve our epidemiologic understanding of skin biopsy outcomes, specifically those of melanocytic origin. Objective: To determine population-based frequencies and distribution of histologically confirmed melanocytic lesions. Design, Setting, and Participants: A natural language processing (NLP)-based analysis of EMR pathology reports of adult patients who underwent skin biopsies at a large integrated health care delivery system in the US Pacific Northwest from January 1, 2007, through December 31, 2012. Exposures: Skin biopsy procedure. Main Outcomes and Measures: The primary outcome was histopathologic diagnosis, obtained using an NLP-based system to process EMR pathology reports. We determined the percentage of diagnoses classified as melanocytic vs nonmelanocytic lesions. Diagnoses classified as melanocytic were further subclassified using the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis (MPATH-Dx) reporting schema into the following categories: class I (nevi and other benign proliferations such as mildly dysplastic lesions typically requiring no further treatment), class II (moderately dysplastic and other low-risk lesions that may merit narrow reexcision with <5-mm margins), class III (eg, melanoma in situ and other higher-risk lesions warranting reexcision with 5-mm to 1-cm margins), and class IV/V (invasive melanoma requiring wide reexcision with ≥1-cm margins and potential adjunctive therapy). Health system cancer registry data were used to define the percentage of invasive melanoma cases within MPATH-Dx class IV (stage T1a) vs V (≥stage T1b). Results: A total of 80 368 skin biopsies, performed on 47 529 patients, were examined. Nearly 1 in 4 skin biopsies were of melanocytic lesions (23%; n = 18 715), which were distributed according to MPATH-Dx categories as follows: class I, 83.1% (n = 15 558); class II, 8.3% (n = 1548); class III, 4.5% (n = 842); class IV, 2.2% (n = 405); and class V, 1.9% (n = 362). Conclusions and Relevance: Approximately one-quarter of skin biopsies resulted in diagnoses of melanocytic proliferations. These data provide the first population-based estimates across the spectrum of melanocytic lesions ranging from benign through dysplastic to malignant. These results may serve as a foundation for future research seeking to understand the epidemiology of melanocytic proliferations and optimization of skin biopsy utilization.
Importance: Population-based information on the distribution of histologic diagnoses associated with skin biopsies is unknown. Electronic medical records (EMRs) enable automated extraction of pathology report data to improve our epidemiologic understanding of skin biopsy outcomes, specifically those of melanocytic origin. Objective: To determine population-based frequencies and distribution of histologically confirmed melanocytic lesions. Design, Setting, and Participants: A natural language processing (NLP)-based analysis of EMR pathology reports of adult patients who underwent skin biopsies at a large integrated health care delivery system in the US Pacific Northwest from January 1, 2007, through December 31, 2012. Exposures: Skin biopsy procedure. Main Outcomes and Measures: The primary outcome was histopathologic diagnosis, obtained using an NLP-based system to process EMR pathology reports. We determined the percentage of diagnoses classified as melanocytic vs nonmelanocytic lesions. Diagnoses classified as melanocytic were further subclassified using the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis (MPATH-Dx) reporting schema into the following categories: class I (nevi and other benign proliferations such as mildly dysplastic lesions typically requiring no further treatment), class II (moderately dysplastic and other low-risk lesions that may merit narrow reexcision with <5-mm margins), class III (eg, melanoma in situ and other higher-risk lesions warranting reexcision with 5-mm to 1-cm margins), and class IV/V (invasive melanoma requiring wide reexcision with ≥1-cm margins and potential adjunctive therapy). Health system cancer registry data were used to define the percentage of invasive melanoma cases within MPATH-Dx class IV (stage T1a) vs V (≥stage T1b). Results: A total of 80 368 skin biopsies, performed on 47 529 patients, were examined. Nearly 1 in 4 skin biopsies were of melanocytic lesions (23%; n = 18 715), which were distributed according to MPATH-Dx categories as follows: class I, 83.1% (n = 15 558); class II, 8.3% (n = 1548); class III, 4.5% (n = 842); class IV, 2.2% (n = 405); and class V, 1.9% (n = 362). Conclusions and Relevance: Approximately one-quarter of skin biopsies resulted in diagnoses of melanocytic proliferations. These data provide the first population-based estimates across the spectrum of melanocytic lesions ranging from benign through dysplastic to malignant. These results may serve as a foundation for future research seeking to understand the epidemiology of melanocytic proliferations and optimization of skin biopsy utilization.
Authors: R Corona; A Mele; M Amini; G De Rosa; G Coppola; P Piccardi; M Fucci; P Pasquini; T Faraggiana Journal: J Clin Oncol Date: 1996-04 Impact factor: 44.544
Authors: A Hunter Shain; Iwei Yeh; Ivanka Kovalyshyn; Aravindhan Sriharan; Eric Talevich; Alexander Gagnon; Reinhard Dummer; Jeffrey North; Laura Pincus; Beth Ruben; William Rickaby; Corrado D'Arrigo; Alistair Robson; Boris C Bastian Journal: N Engl J Med Date: 2015-11-12 Impact factor: 91.245
Authors: Justin A Strauss; Chun R Chao; Marilyn L Kwan; Syed A Ahmed; Joanne E Schottinger; Virginia P Quinn Journal: J Am Med Inform Assoc Date: 2012-07-21 Impact factor: 4.497
Authors: David E Elder; Michael W Piepkorn; Raymond L Barnhill; Gary M Longton; Heidi D Nelson; Stevan R Knezevich; Margaret S Pepe; Patricia A Carney; Linda J Titus; Tracy Onega; Anna N A Tosteson; Martin A Weinstock; Joann G Elmore Journal: J Am Acad Dermatol Date: 2018-03-07 Impact factor: 11.527
Authors: Tracy Onega; Raymond L Barnhill; Michael W Piepkorn; Gary M Longton; David E Elder; Martin A Weinstock; Stevan R Knezevich; Lisa M Reisch; Patricia A Carney; Heidi D Nelson; Andrea C Radick; Joann G Elmore Journal: JAMA Dermatol Date: 2018-10-01 Impact factor: 10.282
Authors: Caitlin J May; Michael W Piepkorn; Stevan R Knezevich; David E Elder; Raymond L Barnhill; Annie C Lee; Martiniano J Flores; Kathleen F Kerr; Lisa M Reisch; Joann G Elmore Journal: J Cutan Pathol Date: 2020-07-17 Impact factor: 1.587
Authors: Joann G Elmore; David E Elder; Raymond L Barnhill; Stevan R Knezevich; Gary M Longton; Linda J Titus; Martin A Weinstock; Margaret S Pepe; Heidi D Nelson; Lisa M Reisch; Andrea C Radick; Michael W Piepkorn Journal: JAMA Netw Open Date: 2018-05
Authors: Michael W Piepkorn; Gary M Longton; Lisa M Reisch; David E Elder; Margaret S Pepe; Kathleen F Kerr; Anna N A Tosteson; Heidi D Nelson; Stevan Knezevich; Andrea Radick; Hannah Shucard; Tracy Onega; Patricia A Carney; Joann G Elmore; Raymond L Barnhill Journal: JAMA Netw Open Date: 2019-10-02
Authors: Linda J Titus; Lisa M Reisch; Anna N A Tosteson; Heidi D Nelson; Paul D Frederick; Patricia A Carney; Raymond L Barnhill; David E Elder; Martin A Weinstock; Michael W Piepkorn; Joann G Elmore Journal: Am J Clin Pathol Date: 2018-08-30 Impact factor: 2.493
Authors: Andrea C Radick; Lisa M Reisch; Hannah L Shucard; Michael W Piepkorn; Kathleen F Kerr; David E Elder; Raymond L Barnhill; Stevan R Knezevich; Natalia Oster; Joann G Elmore Journal: J Cutan Pathol Date: 2020-11-06 Impact factor: 1.458